7- and 10-substituted camptothecins: Dependence of topoisomerase I-DNA cleavable complex formation and stability on the 7- and 10-substituents

Molecular Pharmacology

Volumn 57, Issue 2, 2000, Pages 243-251

  Vladu, Bogdan ^a   Woynarowski, Jan M ^a   Manikumar, Govindarajan ^b   Wani, Mansukhlal C ^b   Wall, Monroe E ^b   Von Hoff, Daniel D ^a   Wadkins, Randy M ^a,c  

^a CTRC Institute for Drug Development   (United States)

^b RTI INTERNATIONAL   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; PLASMID DNA;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; COMPLEX FORMATION; DNA PROTEIN COMPLEX; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STOICHIOMETRY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL DIVISION; CELL NUCLEUS; DNA; DNA TOPOISOMERASES, TYPE I; HUMANS; PLASMIDS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0033952901     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Champoux J (1990) Mechanistic aspects of type-I topoisomerases, in DNA Topology and Its Biological Effects (Wang JC and Cozarelli NR eds) pp 211-242, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
2. Chen AY and Liu LF (1994) DNA Topoisomerases: Essential enzymes and lethal targets. Anna Rev Pharmacol Toxicol 94:194-218.
3. Creaven PJ, Allen LM and Muggia FM (1972) Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: Relation to dose and toxicity. Cancer Chemother Rep 56:573-578.
4. Emerson DL, Besterman JM, Brown HR, Evans MG, Leitner PP, Luzzio MJ, Shaffer JE, Sternbach DD, Uehling D and Vuong A (1995) In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer Res 55:603-609.
5. Gottlieb JA, Guarino AM, Call JB, Oliverio VT and Block JB (1970) Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother Rep 54:461-470.
6. Gutfreund H (1995) Kinetics for the Life Sciences: Receptors, Transmitters, and Catalysts, Cambridge University Press, New York.
7. Hertzberg RP, Caranfa MJ and Hecht SM (1989) On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 28:4629-4638
8. Holm C, Covey JM, Kerrigan D and Pommier Y (1989) Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 49:6365-6368.
9. Hsiang Y-H, Hertzberg R, Hecht S and Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878.
10. Hsiang Y-H, Lihou MG and Liu LF (1989) Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082.
11. Jaxel C, Kohn KW, Wani MC, Wall ME and Pommier Y (1989) Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49:1465-1469.
12. Kawato Y, Aonuma M, Hirota Y, Kuga H and Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191.
13. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sowada S, Miyasaka T and Mutai M (1987) Antitumor activity of 7-ethyl-10-[4-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin against murine tumors. Cancer Res 47:5944-5947.
14. Luzzio MJ, Besterman JM, Emerson DL, Evans MG, Lackey K, Leitner PL, McIntyre G, Morton B, Myers PL, Peel M, Sisco JM, Sternbach DD, Tong WQ, Truesdale A, Uehling DE, Vuong A and Yates J (1995) Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. J Med Chem 38:395-401.
15. McHugh MM, Woynarowski JM, Sigmund RD and Beerman TA (1989) Effect of minor groove binding drugs on mammalian topoisomerase I activity. Biochem Pharmacol 38:2323-2328.
16. Muggia FM, Creaven PJ, Hansen H, Cohen MH and Selawry OS (1972) Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880): Correlation with preclinical studies. Cancer Chemother Rep 56:515-521.
17. Pommier Y, Kohlhagen G, Kohn KW, Leteurtre F, Wani MC and Wall ME (1995) Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc Natl Acad Sci USA 92:8861-8865.
18. Pommier Y, Leteurtre F, Fesen M, Fujimori A, Betrand R, Solary E, Kohlhagen G and Kohn KW (1994) Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 12:530-542.
19. Pommier Y, Pourquier P, Fan Y and Strumberg D (1998) Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1400:83-106.
20. Sawada S, Nokata K, Furuta T, Yokokura T and Miyasaka T (1991) Chemical modification of an antitumor alkaloid camptothecin: Synthesis and antitumor activity of 7-C-substituted camptothecins. Chem Pharm Bull (Tokyo) 39:2574-2580
21. Sawada S, Yokokura T and Miyasaka Y (1995) A-ring or E-lactone modified water soluble prodrugs of 20(S)-camptothecin. Current Pharm Design 1:113-132.
22. Tanizawa A, Fujimori A, Fujimori Y and Pommier Y (1994) Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86:836-842.
23. Tanizawa A, Kohn KW, Kohlhagen G, Leteurtre F and Pommier Y (1995) Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry 34:7200-7206.
24. Valenti M, Nieves-Neira W, Kohlhagen G, Kohn KW, Wall ME, Wani MC and Pommier Y (1997) Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase 1 and in human colon carcinoma SW620 cells. Mol Pharmacol 52:82-87.
25. Wall ME, Wani MC, Cook CE, Palmar KH, MacPhail AT and Sim GA (1966) Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888-3890.
26. Wall ME, Wani MC, Nicholas AW, Manikumar G, Tele C, Moore L, Truesdale A, Leitner P and Besterman JM (1993) Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. J Med Chem 36:2689-2700.
27. Wang JC (1991) DNA topoisomerases: Why so many. J Biol Chem 266:6659-6662.
28. Wang X, Wang L-K, Kingsbury WD, Johnson RK and Hecht SM (1998) Differential effects of camptothecin derivatives on topoisomerase I-mediated DNA structure modification. Biochemistry 37:9399-9408.
29. Wani MC, Ronman PE, Lindley JT and Wall ME (1980) Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogs. J Med Chem 23:554-560.
30. Wani MC and Wall ME (1969) Plant Antitumor Agents. II. The structure of two new alkaloids from Camptotheca acuminata. J Org Chem 34:1364-1367.
31. Woynarowski JM, McCarthy K, Reynolds B, Beerman TA and Denny WA (1994) Topoisomerase II mediated DNA lesions induced by acridine-4-carboxamide and 2-(4-pyridyl)quinolone-8-carboxamide. Anticancer Drug Des 9:9-24.
32. Woynarowski JM, Napier C, Koester SK, Chen SF and Troyer D (1997) Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfluvene (HMAF, MGI 114). Biochem Pharmacol 54:1181-1193.
33. Wu X, Gutfreund H and Chock PB (1992) Kinetic method for differentiating mechanisms for ligand exchange reactions: Application to test for substrate channeling in glycolysis. Biochemistry 31:2123-2128.